Ivermectin, HCQ dropped from revised clinical guidance
The reasons behind dropping Hydroxychloroquine also included no mortality benefit, increases the risk of address drug effect (ADE) when co-administered with Azithromycin
The reasons behind dropping Hydroxychloroquine also included no mortality benefit, increases the risk of address drug effect (ADE) when co-administered with Azithromycin
Health and Human Services Secretary Xavier Becerra said his agency was evaluating whether it can close some of the emergency shelters
